Contribution of Cardiac and Extra-Cardiac Disease Burden to Risk of Cardiovascular Outcomes Varies by Ejection Fraction in Heart Failure

Abstract

In North American HF patients enrolled in the CHARM trials, the relative contribution of cardiac and extra-cardiac disease burden to CV outcomes and death differed depending on LVEF. The high risk of events attributable to non-cardiac disease burden may help explain why cardiac disease-modifying medication proven to be efficacious in HFrEF patients has not proven beneficial in HFpEF.